Heart Failure Connect
4yr
Impact of Anemia and the Effect of Empagliflozin in HFrEF: findings from EMPEROR‐Reduced
Source : https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2409
Corresponding Author João Pedro Ferreira MD, PhD Université de Lorraine, Inserm, Centre d'Investigations Cliniques Plurithématique 1433, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France Cardiovascular...
Conclusions: Anemia was associated with poor outcomes. Empagliflozin reduced new onset anemia throughout the follow-up and improved heart failure and kidney outcomes irrespective of anemia status at baseline.